ID

35073

Description

Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02506361

Lien

https://clinicaltrials.gov/show/NCT02506361

Mots-clés

Versions (1)
  1. 13/02/2019 13/02/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

13 février 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT02506361

Anglais

Eligibility Breast Cancer NCT02506361

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
for inclusion in the study, subjects must fulfil all of the following criteria:
Description

Criteria Fulfill

Type de données

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
1. . signed and dated informed consent indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
Description

Informed Consent | Informed Consent Patient Representative

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C0030701
2. . invasive breast cancer confirmed by histology or cytology with the tumor complete resection.
Description

Invasive carcinoma of breast | Complete excision Tumor

Type de données

boolean

Alias
UMLS CUI [1]
C0853879
UMLS CUI [2,1]
C0015250
UMLS CUI [2,2]
C0027651
3. . patients without remote organs metastasis.
Description

Absence Neoplasm Metastasis Organ Remote

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0027627
UMLS CUI [1,3]
C0178784
UMLS CUI [1,4]
C0205157
4. . the ages of patients ≥ 18 years and ≤70 years.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
5. . patients with positive axillary lymph nodes, or negative axillary lymph nodes plus one of these conditions: triple-negative breast cancer, her- 2(+),ki-67≥15%.
Description

Positive Axillary Lymph Node | Negative Axillary Lymph Node plus Triple Negative Breast Neoplasm | Negative Axillary Lymph Node plus HER2 Positive | Negative Axillary Lymph Node plus Ki67 Measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0677929
UMLS CUI [2,1]
C0279781
UMLS CUI [2,2]
C0332287
UMLS CUI [2,3]
C3539878
UMLS CUI [3,1]
C0279781
UMLS CUI [3,2]
C0332287
UMLS CUI [3,3]
C2348909
UMLS CUI [4,1]
C0279781
UMLS CUI [4,2]
C0332287
UMLS CUI [4,3]
C4049944
6. . the values of aspartate aminotransferase(ast),alanine aminotransferase(alt), alkaline phosphatase(alp), total bilirubin(tbil), urea, crea were less than 2 times of upper limits of normal at the beginning of aromatase inhibitors（ais） therapy.
Description

Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Serum total bilirubin measurement | Urea measurement | Creatinine measurement, serum

Type de données

boolean

Alias
UMLS CUI [1]
C0201899
UMLS CUI [2]
C0201836
UMLS CUI [3]
C0201850
UMLS CUI [4]
C1278039
UMLS CUI [5]
C0523961
UMLS CUI [6]
C0201976
7. . top2α is available to be detected in the primary tumour tissue.
Description

TOP2 Detectable Primary tumor tissue

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012863
UMLS CUI [1,2]
C3830527
UMLS CUI [1,3]
C0677930
UMLS CUI [1,4]
C0040300
8. . patients received the regimens of anthracyclines followed taxanes or containing no taxanes non-dose dense chemotherapy suggested by the guidelines of national comprehensive cancer network （nccn) 2014.
Description

Anthracyclines | Taxanes

Type de données

boolean

Alias
UMLS CUI [1]
C0003234
UMLS CUI [2]
C0796419
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any of the following is regarded as a criterion for exclusion from the study:
Description

Exclusion Criteria Any

Type de données

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1552551
1. . patients is in the period of pregnancy or lactation.
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. . bilateral breast cancer, inflammatory breast cancer or carcinoma in situ.
Description

Bilateral breast cancer | Inflammatory Breast Carcinoma | Carcinoma in Situ

Type de données

boolean

Alias
UMLS CUI [1]
C0281267
UMLS CUI [2]
C0278601
UMLS CUI [3]
C0007099
3. . previous received neo-adjuvant therapy, including chemotherapy, radiotherapy or endocrinotherapy.
Description

Neoadjuvant Therapy | Chemotherapy | Therapeutic radiology procedure | Hormone Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0600558
UMLS CUI [2]
C0392920
UMLS CUI [3]
C1522449
UMLS CUI [4]
C0279025
4. . presence of other life-threatening cancers.
Description

Cancer Other Life Threatening

Type de données

boolean

Alias
UMLS CUI [1,1]
C1707251
UMLS CUI [1,2]
C2826244
5. . any severe concomitant condition: uncontrolled cardiac disease or uncontrolled diabetes mellitus. et al.
Description

Comorbidity Severe | Heart Disease Uncontrolled | Diabetic - poor control

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C0018799
UMLS CUI [2,2]
C0205318
UMLS CUI [3]
C0421258
Retour au début de la page

Similar models

Eligibility Breast Cancer NCT02506361

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Criteria Fulfill
Item
for inclusion in the study, subjects must fulfil all of the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Informed Consent | Informed Consent Patient Representative
Item
1. . signed and dated informed consent indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Invasive carcinoma of breast | Complete excision Tumor
Item
2. . invasive breast cancer confirmed by histology or cytology with the tumor complete resection.
boolean
C0853879 (UMLS CUI [1])
C0015250 (UMLS CUI [2,1])
C0027651 (UMLS CUI [2,2])
Absence Neoplasm Metastasis Organ Remote
Item
3. . patients without remote organs metastasis.
boolean
C0332197 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0178784 (UMLS CUI [1,3])
C0205157 (UMLS CUI [1,4])
Age
Item
4. . the ages of patients ≥ 18 years and ≤70 years.
boolean
C0001779 (UMLS CUI [1])
Positive Axillary Lymph Node | Negative Axillary Lymph Node plus Triple Negative Breast Neoplasm | Negative Axillary Lymph Node plus HER2 Positive | Negative Axillary Lymph Node plus Ki67 Measurement
Item
5. . patients with positive axillary lymph nodes, or negative axillary lymph nodes plus one of these conditions: triple-negative breast cancer, her- 2(+),ki-67≥15%.
boolean
C0677929 (UMLS CUI [1])
C0279781 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C3539878 (UMLS CUI [2,3])
C0279781 (UMLS CUI [3,1])
C0332287 (UMLS CUI [3,2])
C2348909 (UMLS CUI [3,3])
C0279781 (UMLS CUI [4,1])
C0332287 (UMLS CUI [4,2])
C4049944 (UMLS CUI [4,3])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Serum total bilirubin measurement | Urea measurement | Creatinine measurement, serum
Item
6. . the values of aspartate aminotransferase(ast),alanine aminotransferase(alt), alkaline phosphatase(alp), total bilirubin(tbil), urea, crea were less than 2 times of upper limits of normal at the beginning of aromatase inhibitors（ais） therapy.
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0201850 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0523961 (UMLS CUI [5])
C0201976 (UMLS CUI [6])
TOP2 Detectable Primary tumor tissue
Item
7. . top2α is available to be detected in the primary tumour tissue.
boolean
C0012863 (UMLS CUI [1,1])
C3830527 (UMLS CUI [1,2])
C0677930 (UMLS CUI [1,3])
C0040300 (UMLS CUI [1,4])
Anthracyclines | Taxanes
Item
8. . patients received the regimens of anthracyclines followed taxanes or containing no taxanes non-dose dense chemotherapy suggested by the guidelines of national comprehensive cancer network （nccn) 2014.
boolean
C0003234 (UMLS CUI [1])
C0796419 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Exclusion Criteria Any
Item
any of the following is regarded as a criterion for exclusion from the study:
boolean
C0680251 (UMLS CUI [1,1])
C1552551 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
1. . patients is in the period of pregnancy or lactation.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Bilateral breast cancer | Inflammatory Breast Carcinoma | Carcinoma in Situ
Item
2. . bilateral breast cancer, inflammatory breast cancer or carcinoma in situ.
boolean
C0281267 (UMLS CUI [1])
C0278601 (UMLS CUI [2])
C0007099 (UMLS CUI [3])
Neoadjuvant Therapy | Chemotherapy | Therapeutic radiology procedure | Hormone Therapy
Item
3. . previous received neo-adjuvant therapy, including chemotherapy, radiotherapy or endocrinotherapy.
boolean
C0600558 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0279025 (UMLS CUI [4])
Cancer Other Life Threatening
Item
4. . presence of other life-threatening cancers.
boolean
C1707251 (UMLS CUI [1,1])
C2826244 (UMLS CUI [1,2])
Comorbidity Severe | Heart Disease Uncontrolled | Diabetic - poor control
Item
5. . any severe concomitant condition: uncontrolled cardiac disease or uncontrolled diabetes mellitus. et al.
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0018799 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0421258 (UMLS CUI [3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial